Table 2.
Comparison of clinical features in PAN and DADA2 *
| Adult PAN | Childhood PAN | DADA2 | |
|---|---|---|---|
| Average age at diagnosis (yr) | 50 | 9 | 5 |
| Female (%) | 35 | 50 | 50 |
| Clinical features | |||
| Recurrent fever (%) | 60 | 80 | 70 |
| Myalgia / arthralgia (%) | 60 | 70 | 50 |
| Livedo (%) | 20 | 50 | 70 |
| Cutaneous vasculitis (%) | 60 | 90 | 80 |
| Neurologic manifestations (%) | 60 | 30 | 60 |
| CNS involvement (%) | 10 | 20 | 60 |
| PNS involvement (%) | 70 | 20 | 20 |
| GI manifestations (%) | 30 | 40 | 40 |
| Renal manifestations (%) | 40 | 40 | 20 |
| Hypertension (%) | 40 | 30 | 20 |
| Laboratory features ** | |||
| Hemoglobin | ↓ | - | ↓ (50%) |
| WBC | ↑ | - | ↓ (50%) |
| Platelets | ↑ | - | ↓ (20%) |
| IgA | - | - | ↓ (40%) |
| IgM | - | - | ↓ (50%) |
| IgG | - | - | ↓ (30%) |
Bold print highlights areas of major difference between DADA2 and PAN
**
Arrows indicate increased (↑) or decreased (↓) levels compared to healthy controls. The approximate percentage of DADA2 patients with each laboratory feature is provided.